NeuroSense Reports Statistically Significant 65% Reduction in ALS Death Risk with PrimeC in Phase 2b Trial
Summary
NeuroSense Therapeutics announced new long-term survival data from its Phase 2b trial for PrimeC in ALS, showing a statistically significant 65% reduction in the risk of death and over 14 months median survival benefit.
Key Events
-
PrimeC Demonstrates Significant Survival Benefit
New long-term data from the PARADIGM Phase 2b trial showed PrimeC reduced the risk of death by 65% (p=0.0037) in ALS patients compared to placebo.
-
Extended Median Survival
Patients treated with PrimeC achieved an estimated median survival of 36.3 months, a 14-month (70%) improvement over the placebo group.
-
Strengthens Regulatory Position
These findings are expected to substantially strengthen the clinical and regulatory foundation for advancing PrimeC into pivotal late-stage development, building on the recent Australian patent grant for PrimeC on February 9, 2026.
Analysis
This filing provides highly positive and material clinical data for NeuroSense Therapeutics' lead drug candidate, PrimeC, in the treatment of Amyotrophic Lateral Sclerosis (ALS). The statistically significant 65% reduction in the risk of death and a 14-month increase in median survival are substantial outcomes for a devastating neurodegenerative disease with limited treatment options. This data significantly strengthens the clinical and regulatory profile of PrimeC, enhancing its potential for late-stage development and improving the company's position for future capital raises, especially following its recent universal shelf registration.
At the time of this filing, NRSN was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.7M. The 52-week trading range was $0.68 to $2.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.